Navigation Links
An adjuvant chemotherapeutic agent in gastric cancer therapy
Date:2/17/2009

Peritoneal carcinomatosis can be thought of as a series of events that together form a peritoneal metastatic cascade. The peritoneal stromal tissue appears to be a friendly host for tumour proliferation, providing a rich source of growth factors and chemokines known to be involved in tumour metastasis. Till now, our understanding of the molecular mediators that orchestrate this cascade is weakly understood. Astragalus memebranaceus,a traditional chinese herbal medicine used for the treatment of common cold , diarrhea, fatigue anorexia and cardiac diseases. In recent years, it has been proposed that Astragalus may possess anti-apoptosis potential in peritoneal mesothelial cell. In spite of this, the anti-apoptosis effects of Astragalus saponin extract in human peritoneal mesothelial cells during peritoneal carcinomatosishas has not been studied. In this study, the anti-apoptosis effects of Astragalus saponin extract were investigated in human peritoneal mesothelial cells during peritoneal gastric cancer metastasis.

A research article to be published on February 7, 2009 in the World Journal of Gastroenterology addresses this question. The research team led by Professor Hui-Mian Xu from Department of Oncology, The First Affiliated Hospital, China Medical University.Human peritoneal mesothelial cell line HMrSV5 was co-incubated with gastric cancer cell supernatant and/or Astragalus injection. Morphological changes were observed. Apoptosis was determined by transmission electron microscope. Apoptosis was also quantified by two methods: the detection of acridine orange/ethidium bromide-stained condensed nuclei by fluorescent microscopy and flow cytometry. The expressions of Bcl-2 and Bax were evaluated by immunostaining.

After 24h of being treated with gastric cancer cell supernatant, mesothelial cells presented morphological changes, exfoliation happened and naked areas appeared.

Cell supernatant from gastric cancer cell MKN45 were effective in inducing apoptosis in mesothelial cells in a time-dependent manner. Obvious morphological changes of cell apoptosis were found. Astragalus injection could partly suppress these changes, as well as regulate the expressions of Bcl-2 and Bax in mesothelial cells. These findings demonstrated that gastric cancer cell could induce the apoptosis of human peritoneal mesothelial cell through its supernatant. Astragalus injection could inhibit this kind of phenomenon and therefore, might represent an adjuvant chemotherapeutic agent in gastric cancer therapy.


'/>"/>

Contact: Lin Tian
wjg@wjgnet.com
86-105-908-0039
World Journal of Gastroenterology
Source:Eurekalert

Related medicine news :

1. Nanoemulsion-Based Intranasal Influenza Vaccine Adjuvant Triggers Robust Immunity Using Significantly Less Antigen
2. Cancer patients who receive neoadjuvant therapy followed by mastectomy may not need radiation
3. Genomic Health Announces Oncotype DX(R) Provides Additional Prognostic Benefit in Patients Assessed With Adjuvant Online
4. Infectious Disease Research Institute Receives Grant from the Bill & Melinda Gates Foundation for Adjuvant Access and Development
5. A new chemotherapeutic target for hepatocellular carcinoma
6. Senior Market Sales Offers Discounted E&O Insurance for Agents
7. An Oral Agent for the Treatment of Moderate to Severe Psoriasis Would Earn a Higher Patient Share in the United States than in Europe
8. CRi to Distribute VisEn Medicals Portfolio of Fluorescence In Vivo Imaging Agents and Labels in North America
9. Rapid Generic Erosion of Branded Agents, Including Market-Leading Viagra, Will Cause Sales of Erectile Dysfunction Drugs to Remain Flat Over the Next Decade
10. RE/MAX Northern Illinois Real Estate Agents Raises $284,000 For CMN In 2008, An 18 Percent Increase Over Prior Year
11. Aflac Agents and Employees Boost Bone Marrow Registry
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/16/2017)... ... August 16, 2017 , ... Ten outstanding teachers in the Greater Houston area ... will win a visit by a Houston Texans player, two tickets to a Texans ... years old can visit texanschecking.com/stars to nominate their favorite teacher with an essay of ...
(Date:8/16/2017)... Georgia (PRWEB) , ... August 16, 2017 , ... ... in Atlanta, opened their doors. They celebrate 30 years in business this year, ... create an up-to-date, inviting, tranquil space to serve their patients. , It ...
(Date:8/16/2017)... ... August 16, 2017 , ... Maury Regional Health has announced ... draws. By broadly deploying AccuVein devices, Maury Regional Medical Center is making vein visualization ... out of a needle stick and more importantly, helps our staff members locate a ...
(Date:8/16/2017)... ... 2017 , ... A global leader in the treatment of clubfoot, CURE ... Indian states—bringing the country one step closer to eliminating clubfoot as a lifelong disability ... on track to enroll 10,000 children in the clubfoot treatment program in this year ...
(Date:8/16/2017)... ... ... Fusion Flix Inc., a Telly Award Winning, Non Profit Corporation has announced their ... a partnership with the Amazon Video Direct Streaming Distribution Platform. , Their content will ... in 2018. Proceeds will be going to further health research. , Fusion Flix ...
Breaking Medicine News(10 mins):
(Date:8/15/2017)... -- Axium Pharmaceuticals Inc., the creator of the drug Truveta for ... of an IPO. The United States ... of a prescription epilepsy drug being $450.00-$1200.00 for a one month supply. ... AXIUM PHARMACEUTICALS, INC ... staggering figure is the fact that Americans spent $42 billion on anxiety ...
(Date:8/14/2017)... Israel , Aug. 15, 2017  BrainStorm ... adult stem cell technologies for neurodegenerative diseases, announced financial ... "We are in ... 3 trial to investigate NurOwn ® in ALS," ... Officer of BrainStorm. "We have agreements with Mass. General ...
(Date:8/8/2017)... 8, 2017  BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage ... its financial results for the second quarter ended June ... second quarter 2017 and to date: ... programs for the Company,s lead project, BL-8040: ... with BL-8040 as novel stem cell mobilization treatment for ...
Breaking Medicine Technology: